Terri M Wensel

Summary

Affiliation: Samford University
Country: USA

Publications

  1. ncbi Role of metformin in the treatment of gestational diabetes
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, 800 Lakeshore Dr, Ingalls 302, Birmingham, AL, USA
    Ann Pharmacother 43:939-43. 2009
  2. ncbi Pitavastatin: a new HMG-CoA reductase inhibitor
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, Birmingham, AL 35229, USA
    Ann Pharmacother 44:507-14. 2010
  3. ncbi Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, Birmingham, Alabama 35229, USA
    Pharmacotherapy 31:510-23. 2011
  4. ncbi Linaclotide: a novel approach to the treatment of irritable bowel syndrome
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA
    Ann Pharmacother 45:1535-43. 2011

Detail Information

Publications4

  1. ncbi Role of metformin in the treatment of gestational diabetes
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, 800 Lakeshore Dr, Ingalls 302, Birmingham, AL, USA
    Ann Pharmacother 43:939-43. 2009
    ..To evaluate the safety and efficacy of metformin in the treatment of gestational diabetes mellitus (GDM)...
  2. ncbi Pitavastatin: a new HMG-CoA reductase inhibitor
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, Birmingham, AL 35229, USA
    Ann Pharmacother 44:507-14. 2010
    ..To review pitavastatin, the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor and determine its place in the treatment of hypercholesterolemia...
  3. ncbi Effects of denosumab on bone mineral density and bone turnover in postmenopausal women
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, Birmingham, Alabama 35229, USA
    Pharmacotherapy 31:510-23. 2011
    ..Therefore, bisphosphonates will likely remain as first-line therapy. Denosumab should be considered in patients unable to tolerate or who have adherence issues or contraindications to other therapies...
  4. ncbi Linaclotide: a novel approach to the treatment of irritable bowel syndrome
    Terri M Wensel
    McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA
    Ann Pharmacother 45:1535-43. 2011
    ..To review the pharmacology, pharmacokinetics, efficacy, and safety of linaclotide for irritable bowel syndrome (IBS)...